Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: Superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria

A HASUGIAN, H PURBA, Enny Kenangalem, R Wuwung, E Ebsworth, R Maristela, P PENTTINEN, F Laihad, Nicholas Anstey, Emiliana Tijitra, Ric Price

    Research output: Contribution to journalArticle

    Abstract

    Background. Antimalarial drug resistance is now well established in both Plasmodium falciparum and Plasmodium vivax. In southern Papua, Indonesia, where both strains of plasmodia coexist, we have been conducting a series of studies to optimize treatment strategies. Methods. We conducted a randomized trial that compared the efficacy and safety of dihydroartemisinin-piperaquine (DHP) with artesunate-amodiaquine (AAQ). The primary end point was the overall cumulative parasitological failure rate at day 42. Results. Of the 334 patients in the evaluable patient population, 185 were infected with P. falciparum, 80 were infected with P. vivax, and 69 were infected with both species. The overall parasitological failure rate at day 42 was 45% (95% confidence interval [CI], 36%-53%) for AAQ and 13% (95% CI, 7.2%-19%) for DHP (hazard ratio [HR], 4.3; 95% CI, 2.5-7.2; P < .001). Rates of both recrudescence of P. falciparum infection and recurrence of P. vivax infection were significantly higher after receipt of AAQ than after receipt of DHP (HR, 3.4 [95% CI, 1.2-9.4] and 4.3 [95% CI, 2.2-8.2], respectively; P < .001). By the end of the study, AAQ recipients were 2.95-fold (95% CI, 1.2- to 4.9-fold) more likely to be anemic and 14.5-fold (95% CI, 3.4- to 61-fold) more likely to have carried P. vivax gametocytes. Conclusions. DHP was more effective and better tolerated than AAQ against multidrug-resistant P. falciparum and P. vivax infections. The prolonged therapeutic effect of piperaquine delayed the time to P. falciparum reinfection, decreased the rate of recurrence of P. vivax infection, and reduced the risk of P. vivax gametocyte carriage and anemia. � 2007 by the Infectious Diseases Society of America. All rights reserved.
    Original languageEnglish
    Pages (from-to)1067-1074
    Number of pages8
    JournalClinical Infectious Diseases
    Volume44
    Issue number8
    Publication statusPublished - 2007

    Fingerprint Dive into the research topics of 'Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: Superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria'. Together they form a unique fingerprint.

  • Cite this